Genetic Analysis of Signaling Components in Innate Immunity
先天免疫信号成分的遗传分析
基本信息
- 批准号:7670122
- 负责人:
- 金额:$ 23.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAntiviral AgentsAntiviral resistanceAreaAttenuatedBiochemicalCell LineCellsChikungunya virusCollaborationsCritical PathwaysCytoplasmDataDendritic CellsDevelopmentDiagnosticEffectivenessElementsEquilibriumGene ExpressionGeneticHumanImmuneImmune systemImmunityImpairmentInfectionInfluenzaInfluenza A virusInterferon InducersInterferon Type IInterferonsKnowledgeLesionMediatingMissionMolecularMusNatural ImmunityNatureNucleic AcidsOutcomePathogenesisPathway interactionsProteinsResearchSignal PathwaySignal TransductionStagingSystemToll-like receptorsVaccinesVacciniaVaccinia virusViralVirulenceVirulence FactorsVirusVirus DiseasesVirus InhibitorsWorkbasebiodefensedrug discoverygene inductiongenetic analysisimmune resistanceinhibitor/antagonistmembermicrobialnovel strategiesnovel therapeuticspressurereceptorresponsesmall moleculetherapeutic targetviral resistance
项目摘要
Type I interferon (IFN) provides an initial component of innate immune resistance to viral infection and replication
by inducing a large set of antiviral effector proteins capable of inhibiting diverse viruses at multiple points in the
infection. Inherent to the effectiveness of this response are cellular signaling pathways that first trigger IFN gene
induction in response to infection and subsequently trigger IFN-stimulated gene (ISG) expression in response to
secreted IFN. IFN gene induction proceeds through two distinct pathways, a cytosolic signaling system triggered by
viral nucleic acid in the cytoplasm that operates in most infected cells and a transmembrane pathway dependent on
Toll-like receptor (TLR) proteins that is critical in dendritic cells. The essential nature of the IFN system in antiviral
immunity has been demonstrated by genetic and biochemical data, but its ultimate effectiveness is limited by viral
evasion through the action of viral virulence factors that impaire IFN action. The underlying hypothesis of our proposed
research is that through better understaning the molecular mechanisms of IFN induction and action and their
impairment by viral evasion, we will be able to devise novel therapeutics based on augmenting innate immunity and
inhibiting viral evasion. This project focuses on three distinct viruses that each impair the IFN pathway, influenza A
virus, vaccinia virus, and chikungunya virus; will analyze the interaction between viruses and IFN signaling in a unique
set of genetically modified dendritic cells lines; and will develop a platform to screen for small molecule inhibitors of viral
virulence. This work will be performed in close collaboration with other members of the innate immunity team, Drs.
Easier, Garcia-Sastre, and Wu.
This project is well integrated into the mission of the RCE. Innate immunity has emerged as an essential
component of the key focus areas of the RCE, impacting on adaptive immunity and being critical for athe adjuvant
effects of vaccines; providing an important diagnostic indication of infection; and uncovering a novel approach to
therapeutics by targeting the interaction between the innate immune system and virulence factors. Knowledge gained in
these studies will also be applicable to microbial innate immunity that relies on similar mechani
I型干扰素(IFN)提供了对病毒感染和复制的先天免疫抗性的初始组成部分
通过诱导大量抗病毒效应子蛋白,能够抑制多个点的多种病毒
感染。该反应有效性固有的是首次触发IFN基因的细胞信号通路
响应感染,随后触发了IFN刺激的基因(ISG)表达,以响应于
分泌的ifn。 IFN基因诱导通过两种不同的途径进行,这是由胞质信号传导系统触发的
在大多数感染细胞和跨膜途径中起作用的细胞质中的病毒核酸
在树突状细胞中至关重要的Toll样受体(TLR)蛋白。 IFN系统在抗病毒中的基本特性
遗传和生化数据已经证明了免疫力,但其最终有效性受病毒的限制
通过损害IFN作用的病毒毒力因子的作用来逃避。我们提议的基本假设
研究是,通过更好地理解IFN诱导和作用的分子机制及其
通过逃避病毒障碍,我们将能够基于增强先天免疫力和
抑制病毒逃避。该项目着重于每个损害IFN途径的三种不同病毒,流感
病毒,牛ac病毒和基孔肯雅病毒;将分析唯一的病毒和IFN信号之间的相互作用
一组转基因的树突状细胞系;并将开发一个平台以筛选病毒的小分子抑制剂
毒力。这项工作将与先天免疫团队的其他成员密切合作进行。
更容易,加西亚 - astre和吴。
该项目已很好地整合到了RCE的任务中。先天免疫已成为必不可少的
RCE的关键重点区域的组成部分,影响适应性免疫,对辅助剂至关重要
疫苗的作用;提供感染的重要诊断指示;并发现一种新颖的方法
通过靶向先天免疫系统与毒力因子之间的相互作用来进行治疗。获得的知识
这些研究也将适用于依赖类似机械的微生物先天免疫
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David E Levy其他文献
David E Levy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David E Levy', 18)}}的其他基金
A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
基孔肯雅病毒复制子作为抗病毒治疗的平台
- 批准号:
8789899 - 财政年份:2014
- 资助金额:
$ 23.94万 - 项目类别:
Acquisition of an X-Rad 320 Biological Irradiator
购买 X-Rad 320 生物辐照器
- 批准号:
8703903 - 财政年份:2014
- 资助金额:
$ 23.94万 - 项目类别:
Training Program in Molecular Oncology and Immunology
分子肿瘤学和免疫学培训计划
- 批准号:
8761272 - 财政年份:2013
- 资助金额:
$ 23.94万 - 项目类别:
A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
基孔肯雅病毒复制子作为抗病毒治疗的平台
- 批准号:
8302538 - 财政年份:2011
- 资助金额:
$ 23.94万 - 项目类别:
NPM ALK mediated transformation of T lymphocytes
NPM ALK 介导的 T 淋巴细胞转化
- 批准号:
6991316 - 财政年份:2001
- 资助金额:
$ 23.94万 - 项目类别:
NPM ALK mediated transformation of T lymphocytes
NPM ALK 介导的 T 淋巴细胞转化
- 批准号:
7197729 - 财政年份:2001
- 资助金额:
$ 23.94万 - 项目类别:
FUNCTION OF IRF7 IN RESPONSE TO VIRUS INFECTION
IRF7 应对病毒感染的功能
- 批准号:
6196084 - 财政年份:2000
- 资助金额:
$ 23.94万 - 项目类别:
FUNCTION OF IRF7 IN RESPONSE TO VIRUS INFECTION
IRF7 应对病毒感染的功能
- 批准号:
6374366 - 财政年份:2000
- 资助金额:
$ 23.94万 - 项目类别:
相似国自然基金
核苷类抗病毒药物嵌合型核酸纳米载体的构筑及其抗病毒性能研究
- 批准号:52303174
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向病毒核衣壳蛋白质相分离的抗病毒药物发现及机制研究
- 批准号:82302491
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
水环境中抗病毒药物及其转化副产物的识别及生态毒性效应研究
- 批准号:52300245
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
猴痘病毒入侵融合复合物、DNA聚合酶复合物的结构解析以及抗病毒药物的开发
- 批准号:82241081
- 批准年份:2022
- 资助金额:65.00 万元
- 项目类别:专项项目
CCHFV的致病机理及抗病毒药物研究
- 批准号:U22A20336
- 批准年份:2022
- 资助金额:255.00 万元
- 项目类别:联合基金项目
相似海外基金
Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B
开发 RIG-I 激动剂 RNA 来治疗慢性乙型肝炎
- 批准号:
10699796 - 财政年份:2023
- 资助金额:
$ 23.94万 - 项目类别:
Defining the Interplay Between Viral Adaptation and Host Proteostasis
定义病毒适应和宿主蛋白质稳态之间的相互作用
- 批准号:
10587055 - 财政年份:2022
- 资助金额:
$ 23.94万 - 项目类别:
Defining the Interplay Between Viral Adaptation and Host Proteostasis
定义病毒适应和宿主蛋白质稳态之间的相互作用
- 批准号:
10707348 - 财政年份:2022
- 资助金额:
$ 23.94万 - 项目类别:
Defining the role of cytomegalovirus in glioblastoma therapies
定义巨细胞病毒在胶质母细胞瘤治疗中的作用
- 批准号:
10443072 - 财政年份:2022
- 资助金额:
$ 23.94万 - 项目类别:
Defining the role of cytomegalovirus in glioblastoma therapies
定义巨细胞病毒在胶质母细胞瘤治疗中的作用
- 批准号:
10608192 - 财政年份:2022
- 资助金额:
$ 23.94万 - 项目类别: